SEC Form 4 · accession 0000899243-18-019568
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cristina Larkin
Officer — Chief Operating Officer
Period of report
Jul 5, 2018
Accepted (ET)
Jul 6, 2018 · 9:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 5, 2018 | M | 4,000 | $5.90 | A | 5,500 | D | |
| Common Stock | Jul 5, 2018 | S | 4,000 | $17.50 | D | 1,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $5.90 | Jul 5, 2018 | M | 4,000 | D | — | Jul 5, 2027 | Common Stock | 4,000 | 20,434 | D |
Explanation of responses
- F1The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017.
- F2The shares underlying this option vested as to 25% on March 7, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.